Domo signs strategic collaboration agreement with AWS for AI solutions
In a recent stock transaction, Shamik J. Parikh, the Chief Medical (TASE:BLWV) Officer of Humacyte, Inc. (NASDAQ:HUMA), acquired 7,500 shares of the company’s common stock. The shares were purchased at a price of $1.55 each, totaling $11,625. Following this transaction, Parikh now holds 7,500 shares directly. The purchase comes as HUMA shares have shown strong momentum, posting a 21% gain over the past week, though the stock remains volatile with analyst price targets ranging from $3 to $25. InvestingPro subscribers can access comprehensive insider trading analysis and 10+ additional key insights about HUMA. This acquisition reflects Parikh’s continued investment in the biotechnology firm, known for its work in developing bioengineered human tissues and organs. With a market capitalization of $237 million and a healthy current ratio of 2.4, the company maintains strong liquidity despite its development-stage status. According to InvestingPro’s Fair Value analysis, the stock is currently trading slightly above its intrinsic value.
In other recent news, Humacyte reported a narrower fourth-quarter loss of $0.16 per share, surpassing analyst expectations of a $0.25 per share loss. Despite this, the company generated no revenue in the quarter, mirroring the previous year’s results. This lack of revenue comes after the recent FDA approval of Symvess, a bioengineered blood vessel product for extremity vascular trauma. Humacyte has started its commercial launch, shipping initial units to two Level 1 trauma centers, and 34 hospitals have initiated the approval process to purchase Symvess. Analysts at Benchmark maintain a Buy rating with a $17 target, citing the company’s potential to capture significant market share in surgical procedures requiring vascular grafts. BTIG analyst Ryan Zimmerman also retained a Buy rating but adjusted the price target from $10 to $8, noting the early commercial traction of Humacyte’s products. Humacyte plans to file an IND application in 2025 for coronary artery bypass grafting trials and aims for a supplemental application in 2026 to expand Symvess’ uses for dialysis access. The company ended 2024 with $95.3 million in cash, raising an additional $46.6 million through a public stock offering in March 2025.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.